Friday, 16 October 2026European Markets

ALD Stock Was Up By 9.72% Before The Weekend

Loading stream...

(vianews) - the market ended the session with ald (ald.pa) rising 9.72% to €7.01 on friday, following the last session's upward trend. cac 40 jumped 0.54% to €7,957.57, after three sequential sessions in a row of losses, on what was a somewhat up trend exchanging session today.

ald's last close was €6.39, 51.07% under its 52-week high of €13.06.

about ald

ald s.a. provides service leasing and vehicle fleet management services. its products and services include full service leasing, fleet management, outsourcing solutions, and sale and lease back; fleet consultancy; and tools and services for fleet managers and drivers. the company is also involved in trading used cars and light commercial vehicles, and the retail sale of vehicles. the company operates in western europe, central and eastern europe, northern europe, south america, africa, and asia. ald s.a. was incorporated in 1998 and is based in rueil-malmaison, france. ald s.a. operates as a subsidiary of société générale société anonyme.

earnings per share

as for profitability, ald has a trailing twelve months eps of €1.17.

pe ratio

ald has a trailing twelve months price to earnings ratio of 5.99. meaning, the purchaser of the share is investing €5.99 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 14%.

revenue growth

year-on-year quarterly revenue growth grew by 755.9%, now sitting on 15.56b for the twelve trailing months.

dividend yield

as stated by morningstar, inc., the next dividend payment is on may 31, 2023, the estimated forward annual dividend rate is 1.06 and the estimated forward annual dividend yield is 16.45%.

more news about ald (ald.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com